Statistics for The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
Total visits
| views | |
|---|---|
| The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer | 87 |
Total visits per month
| views | |
|---|---|
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
File Visits
| views | |
|---|---|
| nihms-1624615.pdf | 75 |
Top country views
| views | |
|---|---|
| United States | 68 |
| Canada | 2 |
| Malaysia | 2 |
| Belgium | 1 |
| China | 1 |
| France | 1 |
| Russia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 40 |
| Fairfield | 8 |
| Houston | 4 |
| Ann Arbor | 2 |
| Cambridge | 2 |
| San Francisco | 2 |
| Toronto | 2 |
| Baltimore | 1 |
| Chicago | 1 |
| Moscow | 1 |
| Nanterre | 1 |
| Seremban | 1 |
| Washington | 1 |
| Zaventem | 1 |